13/03/2026
Pilot study of a topical magnesium preparation to treat hypomagnesaemia in patients with an ileostomy
Jeremy Nightingale 1 , Ibrahim Al Bakir 2 , Franklin Adaba 1
Affiliations expand
PMID: 41648083 PMCID: PMC12851353 DOI: 10.1016/j.intf.2024.100018
Full text links Cite
Abstract
Introduction: Patients with a high output ileostomy often have hypomagnesaemia. This study aimed to determine if a magnesium chloride hexahydrate spray would maintain or increase serum magnesium in ileostomy patients with hypomagnesaemia.
Methods: Outpatients with an ileostomy and having chronic hypomagnesaemia (serum magnesium 0.10 mmol/L at week 6, or the avoidance of a planned magnesium infusion. Serum vitamin D and aldosterone levels, and a 24-hour urinary magnesium concentration were measured.
Results: 6 patients completed the study, all had normal vitamin D levels (>45 nmol/L), and 5 of 6 had urinary magnesium concentrations below 0.28 mmol/L. 2 patients had a rise in serum Mg+2 of 0.27 and 0.13 mmol/l respectively and one avoided their planned six-weekly magnesium infusion, No patient had a fall in serum Mg+2 of more than 0.07 mmol/L. Serum and whole cell Mg+2 correlation was linear (r = 0.9181, p < 0.0001). All 6 patients complained of muscle cramping at enrolment; 5 reported an improvement or complete resolution by week 3. Serum aldosterone levels were high at the start in 4 and reduced in 3. Urine magnesium concentration increased in 2.
Conclusions: A topical magnesium chloride hexahydrate spray maintains or improves serum magnesium levels in patients with an ileostomy and hypomagnesaemia and prevents muscle cramps.
